1. The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma
   Katalin Piroska Kiss et al, 2018, Leukemia & Lymphoma CrossRef
2. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity
   Eleonora Pozzi et al, 2022, Pharmacogenomics in Drug Discovery and Development CrossRef
3. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics
   Andreas A. Argyriou et al, 2017, Nature Reviews Neurology CrossRef
4. Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
   Yuki Fujimoto et al, 2021, Cancers CrossRef
5. Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment
   Roser Velasco et al, 2019, Journal of the Peripheral Nervous System CrossRef
6. Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
   Antonio Sanz-Solas et al, 2023, Journal of Personalized Medicine CrossRef
7. Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
   Lavisha Goel et al, 2024, The American Journal of the Medical Sciences CrossRef